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Effects of Obesity-Inducing Ventromedial Hypothalamic
Lesions on Pulsatile Growth Hormone and Insulin
Secretion: Evidence for the Existence of a Growth
Hormone-Releasing Factor*
ROELOF EIKELBOOMf AND GLORIA SHAFFER TANNENBAUM^
Division of Endocrinology, Department of Medicine, McGill University-Montreal Children's Hospital
Research Institute, and the Departments of Pediatrics, and Neurology and Neurosurgery, McGill
University, Montreal, Quebec H3H1P3, Canada

GH peaks or to alter significantly the 6-h GH secretory profile
of VMH-lesioned animals. In contrast, the administration of
SRIF antiserum to sham-operated controls caused a significant
elevation of GH trough levels. In a second study, obese VMHlesioned rats exhibited reduced pituitary GH concentrations
compared to sham-operated controls.
The finding of a lack of effect of SRIF antiserum in VMHlesioned rats provides good evidence that the suppression of GH
pulses observed in response to lesions of the VMH is due to
interruption of stimulatory pathways involved in GH regulation,
namely GH-releasing factor neurons. The results suggest that
the ultradian surges of GH release are dependent on the release
of GH-releasing factor from the VMH-arcuate nucleus region of
the brain. The data are consistent with the view that the obesity
and GH suppression of the VMH syndrome reflect the disruption
of two different neuronal systems. (Endocrinology 112: 212,
1983)

ABSTRACT. The nature of and neural mechanisms involved
in GH and insulin responses to obesity-inducing ventromedial
hypothalamic (VMH) lesions, which infringed on the arcuate
nucleus, were examined in freely moving chronically cannulated
male rats. Sequential 6-h GH and 3-h insulin and glucose secretory profiles were obtained in VMH-lesioned and sham-operated
control rats. Obese VMH rats exhibited hyperinsulinemia with
marked fluctuations in plasma insulin levels in the presence of
normoglycemia. A striking suppression in both amplitude and
duration of GH secretory episodes was observed, with GH peak
amplitudes rarely exceeding 90 ng/ml compared to 500 ng/rnl in
sham-operated controls (mean 6-h plasma GH level, 17.6 ± 6.0
vs. 154.1 ± 17.8 ng/ml; P < 0.001). The periodicity of the GH
rhythm was maintained, but light-dark entrainment of the GH
pulses was lost. Passive immunization with a specific antiserum
to somatostatin (SRIF) failed to restore the amplitude of the

L

ESIONS of the ventromedial hypothalamus (VMH)
4 result in distinct behavioral and physiological abnormalities (labeled the VMH syndrome), the best
known of which are hyperphagia, hyperinsulinemia, and
obesity (1, 2). Since the first experiments by Hetherington and Ranson (3), it has been well documented that
animals with VMH lesions show reduced linear growth
(4-7). Subsequent studies have suggested an impairment
in GH secretion, since both weanling (8, 9) and adult (10)
VMH-lesioned rats exhibit suppressed plasma GH levels.
These studies, however, were carried out before delinea-

tion of the ultradian rhythm for GH secretion in the rat
(11) and were performed in animals that did not exhibit
the classic VMH lesion-induced increase in body weight.
Furthermore, the mechanism mediating the GH suppression in response to VMH lesions remains to be elucidated.
It is currently believed that central nervous system control of GH secretion is achieved via the complex interaction of two hypothalamic hormones: a GH-releasing
factor (GRF), as yet unidentified, and a GH releaseinhibiting factor, the tetradecapeptide somatostatin
(SRIF) (12). If the GH suppression observed in VMHlesioned rats is due to hypersecretion of SRIF, administration of a specific antiserum to SRIF should result in
an immediate and marked recovery of GH secretion, as
occurs in other forms of SRIF-mediated GH suppression
(13-16). Therefore, the first study in the present report
was undertaken to characterize the dynamics of the GH
rhythm in obese VMH-lesioned rats and to assess the
involvement of endogenous SRIF in this response.
Plasma insulin and glucose were simultaneously moni-
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tored. In addition, a second study was designed to investigate changes in the pituitary GH concentration in view
of previously reported inconsistencies regarding the effects of VMH lesions on the pituitary GH concentration
(6, 8, 9, 17-19).
Materials and Methods
Animals and surgery
Adult male Sprague-Dawley rats, weighing 300-350 g at the
start of each experiment, were obtained from Charles River
Canada (St. Constant, Quebec). Chronic intracardiac venous
cannulae were implanted under sodium pentobarbital (50 mg/
kg, ip) anesthesia, as previously described (11). At the same
time, electrodes, made from 00 stainless steel insect pins insulated except for 0.4 mm at the tip, were stereotaxically inserted,
bilaterally, into the VMH. With the incisor bar at —3 mm,
coordinates were: 2.3 mm posterior to bregma, 0.6 mm lateral
to the midline, and 9.1 mm below the dura. Lesions were
produced using a Grass Lesion Maker (model DCLM5A, Grass
Instrument Co., Quincy, MA) and direct anodal currents ranging from 1 mA for 18 sec to 2 mA for 15 sec. Sham-operated
control rats were treated identically to VMH-lesioned rats, but
the lesion maker was not turned on.
Experimental procedure
After surgery, the animals were placed directly in isolation
test chambers (lights on between 0600-1800 h). Purina rat chow
and tap water were available ad libitum, and body weight was
monitored daily. Only lesioned rats exhibiting a daily weight
gain more than 3 SD above that of sham-operated controls were
selected for study of the classic VMH obese syndrome. After
recovery of preoperative body weight (5-11 days for shams; 2-4
days for VMH-lesioned rats), a 6-h hormonal profile was obtained from both groups of rats by withdrawing blood (0.45 ml)
every 15 min from 1000-1600 h. To assess the role of endogenous
SRIF, two additional 6-h profiles were obtained from the VMHlesioned animals. Nine to 13 days postsurgery, VMH-lesioned
rats were administered 1 ml normal sheep serum (NSS), iv,
after removal of the first blood sample. After a minimum
interval of 3 days, these rats received 1 ml of a specific SRIF
antiserum (SRIF AS) at the same time point. Sham-operated
rats received a similar 1-ml injection of SRIF AS. The SRIF
AS used in these experiments was identical to that described in
our previous passive immunization studies (15, 16). On the test
days, food was removed 1.5-2 h before the start of sampling
and returned at 1600 h. All blood samples were immediately
centrifuged, and plasma was separated and stored at —20 C for
subsequent assay of GH, insulin, and glucose. While plasma GH
levels were measured for the full 6 h, plasma insulin and glucose
levels were determined only for the first 3 h.
In the second experiment, two groups of rats received either
VMH or sham lesions, as described above. Body weight and 24h food intake were monitored daily, and the same weight
criterion was used for inclusion in the VMH-lesioned, obese
(VMH-obese) group. Sixteen days after surgery, both groups
were killed by rapid decapitation, and trunk blood was collected.

The pituitary gland was removed, weighed, homogenized in 2
ml 0.05 M NaHCO3-Na2CO3 buffer, pH 9.96, and centrifuged at
2000 x g for 30 min. The supernatant was removed and stored
at —20 C until subsequent assay for GH.
At the termination of both experiments, the brains of all
lesioned animals were stored in 10% formaldehyde. Coronal
sections (28 jitm) were made and stained with thionine. The
extent and location of the lesions were determined by light
microscopy, using the atlas of Pellegrino and Cushman (20).
Hormone assays
Plasma and pituitary rat GH concentrations were determined
in duplicate by double antibody RIA using materials supplied
by the NIAMDD (Bethesda, MD). The averaged plasma and
pituitary GH values are reported in terms of the rat GH
reference preparation (GH-RP-1). Plasma immunoreactive insulin (IRI) was measured by a dextran-coated charcoal method
(21) using guinea pig antiporcine insulin serum. Purified crystalline rat insulin (lot 615-D63-12-2, courtesy of Dr. R. Chance,
Eli Lilly Co., Indianapolis, IN) served as a reference standard.
Plasma glucose was measured by an automated glucose oxidase
method (Glucose Analyzer 2, Beckman Instruments, Palo Alto,
CA).
Antibody titers in plasma of rats after the administration of
SRIF AS
Antibody titers in plasma of SRIF AS-treated, VMH-lesioned
rats were assessed by determining the ability of aliquots of rat
plasma obtained 1 min before and 15 min, 3 h, and 6 h after
SRIF AS administration to bind [125I-Tyr']SRIF. Plasma samples from each rat were diluted 1:100 in the SRIF RIA assay
buffer, and binding to labeled SRIF was determined under the
conditions used for RIA of SRIF (22).
Statistical analyses
In the first experiment, overall comparisons between groups
were made using an analysis of variance. Individual comparisons after analysis of variance were made using the NewmanKeuls test (23). In the second experiment, statistical comparisons between the two groups were made with Student's twotailed t test.

Results
Behavioral and histological analyses
Behaviorally, VMH-obese rats were highly irritable,
aggressive, and difficult to handle compared to shamoperated controls. VMH-lesioned animals (n = 6) recovered from surgery and gained weight more rapidly
than did sham-operated control rats (n = 7; mean daily
weight gain, 7.2 ± 0.7 vs. 3.0 ± 0.2 g, respectively).
VMH-obese rats exhibited bilateral lesions that destroyed over 80% of the VMH and also resulted in appreciable damage to the arcuate (ARC) nucleus. A representative coronal section showing the largest extent of a
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typical lesion is illustrated in Fig. 1. The antero-posterior
extent was from just caudal to the anterior hypothalamus
to just rostral to the lateral mammillary nucleus [6.4-4.8
in the atlas of Pellegrino and Cushman (20)]. The lesions
did not extend through the base of the brain, and the
median eminence was spared. Laterally, the lesions
reached the fornix, and in most animals, the walls of the
third ventricle were distended.
Effects of VMH lesions on GH, IRI, and glucose secretory profiles
Figure 2 shows representative 6-h plasma GH and 3-h
plasma IRI and glucose secretory patterns in a shamoperated animal in comparison to those in an obeseVMH rat. In sham animals, plasma IRI levels remained
low (rarely exceeding 2.0 ng/ml) and fluctuated minimally over the 3-h period (Fig. 2A). In contrast, plasma
IRI levels in VMH-lesioned rats were markedly elevated
and showed wide and rapid fluctuations, with most peak
IRI values ranging between 3-10 ng/ml (Fig. 2B). Mean
3-h plasma IRI levels were significantly elevated in
VMH-lesioned rats compared to those in sham-operated
controls (3.59 ± 0.83 vs. 0.99 ± 0.18 ng/ml; P < 0.05;
Table 1). Plasma glucose levels remained stable throughout the sampling period in both groups, and no significant
difference in the mean 3-h plasma glucose level was
observed (Table 1).
Sham-operated animals exhibited the typical pulsatile
pattern of GH secretion; two major episodes of GH
secretion were evident during the 6-h sampling period.
The GH secretory episodes had a rapid onset and were
multiphasic in nature, with many peak GH values exceeding 500 ng/ml. Intervening trough levels were generally undetectable (<6.2 ng/ml, the least detectable
concentration in our rat GH assay; Fig. 2A). In striking
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FIG. 2. Individual representative 6-h plasma GH and 3-h plasma IRI
and glucose secretory profiles in a sham-operated rat (A) in comparison
to those in an obese VMH-lesioned rat (B). Arrows indicate plasma
GH values (>) 350 ng/ml.
TABLE 1. Mean plasma GH, IRI, and glucose levels in sham-operated
and VMH-lesioned rats

Experimental group
Sham lesion (7)
VMH lesion (6)
VMH lesion + NSS (5)
VMH lesion -I- SRIF AS
(4)
Sham lesion + SRIF AS
(4)

Mean 6-h
plasma GH
level (ng/ml)

Mean 3-h
plasma IRI
level (ng/
ml)

Mean 3-h
plasma glucose level
(mg/dl)

154.1 ± 17.8
17.6 ± 6.0"
21.2 ± 9.6
23.4 ± 7.1C

0.99 ± 0.18
3.59 ± 0.83*
2.59 ± 1.17
3.86 ± 1.14

140.7 ± 2.4
137.5 ± 5.4
130.4 ± 7.6
133.9 ± 6.8

177.4 ± 34.8

1.19 ± 0.36

137.9 ± 3.8

Values given are the mean ± SEM; the number of animals in each
group is shown in parentheses.
a
P < 0.001 vs. sham lesion.
b
P < 0.05 vs. sham lesion.
c
P < 0.005 vs. sham lesion + SRIF AS.

FIG. 1. A photomicrograph (X31) of a coronal section of the ventral
hypothalamus illustrating the largest extent of a typical bilateral electrolytic VMH lesion.

contrast, the 6-h GH profile of obese-VMH rats showed
a marked suppression in amplitude and duration of GH
secretory episodes. In these rats, peak GH levels rarely
exceeded 90 ng/ml, and a large proportion of plasma GH
values were undetectable (Fig. 2B). When distinct epi-
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sodes were discernible (four of six rats), the characteristic
ultradian rhythm of GH secretion was evident. The mean
period of the GH rhythm in VMH-lesioned rats (3.06 ±
0.28 h) was similar to that observed in sham-operated
controls (3.32 ± 0.22 h). However, there was no evidence
of entrainment of the GH pulses to the light-dark (L-D)
cycle in VMH-lesioned rats; GH secretory bursts occurred randomly throughout the 6-h sampling period.
Figure 3 illustrates the mean 6-h plasma GH levels of the
two groups of rats. It is evident that mean plasma GH
levels were severely suppressed in VMH-lesioned animals
(17.6 ± 6.0 vs. 154.1 ± 17.8 ng/ml; P < 0.001; Table 1).
Furthermore, distinct peaks and troughs were not observed in the mean 6-h GH profile of these rats (Fig. 3B).
This is in contrast to the entrained pattern of GH secretion observed in sham-operated control rats (Fig. 3A).
Effects of SRIF AS on GH, IRI, and glucose secretory
profiles in obese-VMH rats
Individual GH, IRI, and glucose secretory profiles in a
VMH-lesioned rat administered NSS were compared to
those of the same rat administered SRIF AS 5 days later
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(Fig. 4). In both cases, plasma IRI levels continued to be
elevated and fluctuated markedly. The administration of
SRIF AS had no significant effect on either plasma IRI
or glucose levels (Table 1).
The GH profiles of VMH-lesioned rats receiving NSS
still showed the marked suppression in GH pulse amplitude (Figs. 4A and 5), similar to that described above.
Administration of SRIF AS to these rats failed to restore
the amplitude of the GH pulses or significantly alter the
GH secretory profile (Figs. 4B and 5). While plasma GH
levels were slightly elevated 15 min post-SRIF AS administration, this effect was not significant. In addition,
GH trough values were only minimally elevated compared to those of NSS controls (Fig. 5). There was no
significant difference in mean peak, trough, or 6-h plasma
GH level in VMH-lesioned rats administered SRIF AS
compared to those given NSS (Fig. 5 and Table 1).
Figure 6 illustrates the plasma GH, IRI, and glucose
responses to SRIF AS in a sham-operated control rat
whose normal profile is shown in Fig. 2A. In contrast to
what was observed in VMH-lesioned rats, the administration of SRIF AS caused a brief surge of GH secretion
within 15-45 min after injection and significant elevation
of subsequent GH trough levels. Plasma GH trough
values in these animals never fell below 30 ng/ml during
the first 3 h after SRIF AS injection and did not reach
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FIG. 3. Effects of VMH lesions on mean 6-h plasma GH levels. Vertical
lines represent the SEM. The number of animals in each group is shown
in parentheses.
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FIG. 4. Individual representative 6-h plasma GH and 3-h plasma IRI
and glucose secretory patterns in the same VMH-lesioned rat administered NSS (A) or SRIF AS 5 days later (B). Curved arrows indicate
the time of iv injection.
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FIG. 6. Effects of SRIF AS on plasma profiles of GH, IRI, and glucose
in a sham-operated rat whose normal profile is shown in Fig. 2A. The
curved arrow indicates the time of iv injection.

undetectable levels throughout the 6-h sampling period.
The mean GH trough level of sham-operated, SRIF AStreated rats was significantly (P < 0.01) higher than that
of all other groups (Fig. 5). However there was no significant effect of SRIF AS on either mean amplitude of
GH peaks (Fig. 5) or mean 6-h plasma GH level (Table
1). There was also no significant effect of SRIF AS on
either plasma IRI or glucose levels in sham-operated,
SRIF AS-treated rats (Table 1).
SRIF binding of rat plasma after SRIF AS administration
The mean binding of a 1:100 dilution of plasma 1 min
before and 15 min, 3 h, and 6 h after SRIF AS treatment

was found to be 1.4 ± .3%, 42.2 ± 1.4%, 39.8 ± 0.7%, and
36.1 ± 1.0%, respectively. Although the binding at 1600
h was significantly less than that at 1015 h {P < 0.05), it
was still substantial.
Effect of VMH lesions on pituitary GH concentration
Table 2 documents that the obese-VMH rats in the
second experiment exhibited hyperinsulinemia and normoglycemia similar to those observed in Exp 1. Furthermore, not unexpectedly, the VMH-lesioned rats were also
hyperphagic (mean daily food intake, 52.6 ± 5.0 vs. 33.3
± 1.5 g in sham-operated controls). Sixteen days after
surgery, lesioned rats showed a significant reduction in
pituitary wet weight and in pituitary GH content and
concentration compared to values in sham-operated controls (Table 2).

Discussion
The finding that obese-VMH rats exhibit hyperinsulinemia in the presence of normoglycemia confirms similar
observations in previous studies (1, 2). Of interest in the
present study is the pulsatile nature of IRI secretion
observed in VMH-lesioned animals. Basal plasma IRI
levels showed wide oscillations over the 3-h sampling
period (while plasma glucose levels remained stable), a
finding that was probably missed in earlier studies in
which only single blood samples were obtained. The
mechanism mediating the stimulation of IRI secretion
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TABLE 2. Effect of VMH lesions on the pituitary GH concentration
Pituitary
Group

Sham lesion (9)
VMH lesion (8)

Daily wt gain Daily food consumption
(g)
4.7 ± 0.2
8.7 ± 0.7

Plasma IRI
(ng/ml)

33.3 ± 1.5
52.6 ± 5.0*

Plasma glucose
(mg/dl)

Wet wt
(mg)

1.31 ± 0.25
131.3 ± 4.1
12.01 ± 0.46
8.76 ± 1.52C
135.3 ± 5.7
8.95 ± 0.50c
Values given are the mean ± SEM; the number of animals in each group is shown in parentheses.
a
Based on four animals per group.
6
P<0.01.
c
P < 0.001.

has been variously attributed to either direct disruption
of neural connections between the hypothalamus and
pancreas (e.g. vagus nerve) (24) or indirectly to a humoral
factor(s) released after hypothalamic injury (25, 26). It is
possible that the oscillations in plasma IRI are the result
of disinhibition of a recently described intrinsic pancreatic IRI rhythm (27). Further work is necessary to
clarify the mechanism responsible for these IRI fluctuations and to determine whether the other pancreatic
hormones show similar oscillations as a result of VMH
damage.
The ultradian GH rhythm was dramatically altered in
obese-VMH rats. Their plasma GH profiles revealed a
marked reduction in both amplitude and duration of GH
secretory episodes compared to those in sham-operated
control animals. These results indicate that GH secretion
is severely impaired in obese as well as nonobese VMHlesioned rats and provide further support for the hypothesis that the VMH region of the brain;contains the neural
substrates governing pulsatile GH secretion (10, 12, 28).
The minimal episodic GH release observed in the present
study may reflect residual functioning of this system.
The finding that the periodicity of the GH rhythm was
maintained while L-D entrainment of the GH pulses was
lost suggests that different neural circuits subserve these
two parameters of the GH rhythm. The L-D entrainment
of the GH rhythm has been shown to be disturbed by
suprachiasmatic lesions (29) as well as by knife cuts
anterior to the VMH (30), a pathway that was probably
disrupted by the present VMH lesions.
The findings on GH in the present study are very
similar to those recently reported in rats neonatally
administered monosodium glutamate, an agent which
selectively destroys neuronal perikarya in the ARC nucleus of the hypothalamus but spares the VMH (31-33).
This raises a question as to the involvement of the VMH,
per se, in GH regulation. Since the present lesions infringed on the ARC nuclei, it is possible that the observed
aberrations of the GH rhythm are due solely to the ARC
damage. On the other hand, evidence implicating the
VMH as an important neural locus harboring the puta-

GH content
(jug/gland)

1731.0 ± 127.9
790.0 ± 108.4'

GH cone,
wet
wt)
144.2 ± 8.2
87.2 ± 8.0c

tive GRF neurons is impressive in that electrical stimulation of the VMH nuclei produced consistent rises in
plasma GH (34-36), although current spread to the ARC
cannot be ruled out in these studies. Furthermore, Bernardis and Frohman (9) demonstrated significant decreases in basal plasma GH levels in weanling rats as a
result of small lesions limited to the VMH, and reported
progressive decreases as lesion size increased, with consequent infringement on the ARC nuclei. Taken together,
these findings suggest that both the VMH and ARC
regions of the central nervous system are stimulatory to
GH secretion.
One potential explanation for the observed changes in
plasma GH levels may be related to direct pituitary
dysfunction. In the present study, both pituitary wet
weight and pituitary GH concentration were significantly
reduced 16 days after the lesion. These results are in
agreement with the majority of previous reports (6, 8, 9,

19). Only those studies in which the pituitary GH concentration was measured within 48 h after surgery (17,
18) report no effect of the lesion, suggesting that the
pituitary GH depletion is gradual. A similar reduction of
the pituitary GH concentration has been reported in
most studies of monosodium glutamate-treated rats (31,
37), but not all (33). It is unlikely, however, that the
plasma GH suppression was due solely to pituitary insufficiency for the following reasons. First, the plasma
GH suppression should then parallel the pituitary disturbance; thus, the effect should be minimal early after
the lesion and then gradually increase, but no such time
course was observed in the present study. Second, the
pituitary gland is considered to maintain its function in
VMH-lesioned animals, since TRH has been- shown to
cause GH release (19, 38) despite a reduction in pituitary
wet weight and GH content (19). Finally, in another
model of hypothalamic injury (periventricular lesions),
basal plasma GH levels have been shown to be elevated
or at least normal in the face of significant reductions in
the pituitary GH concentration (39). Thus, it seems
reasonable to conclude that the suppression of GH pulse
amplitude observed in VMH-lesioned animals is a direct
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result of central nervous system intervention.
A second possible explanation may be related to disruption of the somatostatinergic neuronal system involved in GH regulation. That is, the GH suppression
could be due to increased release of SRIF into the hypophyseal portal circulation. The finding that passive
immunization with a specific antiserum to SRIF failed to
restore the amplitude of GH pulses or to alter significantly the GH secretory profile of VMH-lesioned rats
argues against this possibility. These findings differ from
our previous passive immunization studies in which the
same SRIF AS resulted in both a restoration of high
amplitude GH pulses and an increase in mean plasma
GH levels in starved (15) and diabetic (16) rats exhibiting
suppressed plasma GH levels. It is unlikely that inadequate passive immunization can account for the lack of
effect, since significant SRIF antibody titers were present
throughout the sampling period. The results indicate
that increased SRIF release is not the mechanism
whereby VMH lesions cause suppression of GH secretion.
These data provide good evidence that the suppression
of GH pulses observed in response to VMH lesions is due
to interruption of stimulatory pathways involved in GH
regulation, e.g. putative GRF neurons. The findings suggest that the ultradian surges of GH release in the rat
are dependent on the release of GRF from the VMHARC region of the brain.
In addition, VMH-lesioned rats did not exhibit the
typical elevation of GH trough levels after SRIF AS
administration, a response that was evident in sham rats
of the present study and has previously been well documented to be the major effect of SRIF AS in normal rats
in both this (40, 41) and other laboratories (42). It has
been reported that lesions of the VMH result in an
approximately 50% decrease in median eminence SRIF
(43). Thus, in addition to disruption of the GRF system,
SRIF release into the hypophyseal portal circulation may
also be impaired in VMH-lesioned animals. A similar
lack of response to SRIF AS administration has been
documented in anesthetized rats exposed to ablation of
the medial basal hypothalamus (MBH), indicating that
an intact MBH may be necessary to elicit the GH response to SRIF AS (44). It is highly unlikely that the
GH suppression in VMH-lesioned rats is due to disruption of SRIF release, since the results of several previous
studies indicate that selective lesions of the primary
somatostatinergic neuronal system, including the anterior hypothalamic-preoptic area (45, 46) or separation of
this area from the MBH (30, 47), markedly augment
plasma GH levels.
The joint occurrence of VMH lesion-induced obesity
and GH suppression raises the possibility that they may
be causally related. It is known that in man, obesity
results in impaired GH release, which is restored when
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the obesity is corrected (48). However, it is unlikely that
the GH suppression observed in the present study is
secondary to the obesity, since similar suppression has
been reported in nonobese, VMH-lesioned animals (10).
The possibility that the GH suppression plays a role in
producing the obesity must be considered. GH is known
to influence the intermediary metabolism of lipids; it
induces mobilization of fat from adipose tissue, and impaired GH secretion could result in a greater accumulation of fat (49). Furthermore, it has been reported that
GH administration to hypophysectomized, VMH-lesioned rats prevents the lesion-induced obesity (50).
However, marked obesity has also been observed in the
presence of elevated plasma GH levels in animals with
surgical isolation of the MBH (30, 47, 51). Thus, it is
possible to observe hypothalamic obesity in rats exhibiting both suppression and hypersecretion of GH. These
findings tend to confirm an earlier suggestion (9) that in
the VMH-lesioned rat, the resulting obesity and GH
disturbance reflect the disruption of two different neuronal systems.
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